Regeneron Exec Says Co. Eligible To Receive $1B In Potential Milestone Payment With Start Of First Late-Stage Trial As Part Of Deal

Regeneron Pharmaceuticals has announced that it is eligible to receive a potential milestone payment of $1 billion following the initiation of its first late-stage trial. This milestone is part of a previously established deal. The news may impact investor sentiment and stock performance for Regeneron, which trades under the ticker REGN.